Gazzola M V, Collins N H, Tafuri A, Keever C A
Bone Marrow Transplantation Service, Memorial Sloan-Kettering Cancer Center, New York, New York.
Exp Hematol. 1992 Feb;20(2):201-8.
Human interleukin 3 (IL-3) is a multipotential cytokine that supports the growth of early hematopoietic progenitors and promotes their response to other, later-acting cytokines. We found that IL-3 was able to induce the expression of interleukin 2 (IL-2) receptor (IL-2R) (CD25) on a subset of early myeloid cells in normal human bone marrow that had been first depleted of mature hematopoietic cells and E-rosette-positive T cells by treatment with soybean lectin and sheep erythrocytes (SBA-E-BM). Immunofluorescence analysis revealed that the CD25+ cells were contained almost entirely within the lymphoblastoid gate of the IL-3-cultured marrow. CD25 was undetectable on freshly isolated marrow and less than 10% CD25+ cells could be detected following liquid culture at 37 degrees C in the presence of 10% human serum, 10% fetal calf serum, or under serum-free conditions. Addition of IL-3 (100 U/ml) significantly increased the expression of CD25 to 37%, 31%, and 24%, respectively. CD25 could also be induced by granulocyte-macrophage colony-stimulating factor (GM-CSF), but no IL-2R was detectable following exposure to granulocyte colony-stimulating factor (G-CSF), macrophage colony-stimulating factor (M-CSF), interleukin 1 (IL-1), interleukin 4 (IL-4), or IL-2. Expression of CD25 was dependent on the dose of IL-3 or GM-CSF added and was maximal within 24 h of exposure. Two-color immunofluorescence analysis demonstrated that CD25 was not expressed by cells of lymphoid lineage or by mature monocytes, but rather was present on cells that coexpressed CD13, CD33, CD34, MY8, and HLA-DR, and that lacked CD14 or CD11b, thus placing the CD25+ cells at or near the myeloblast stage of differentiation. An identical phenotype was found for CD25+ cells induced by GM-CSF. Cycloheximide completely inhibited the IL-3-induced expression of CD25, indicating the necessity for protein synthesis, and although most of the CD25+ cells were in G0/G1 phase, 25% of the cells were in S or G2M phase, indicating that receptor expression was not cell-cycle dependent. The p75 chain of IL-2R was not detected on the CD25+ cells. IL-3 was also found to directly induce CD25 in greater than 46% of SBA-E-BM enriched for CD34+ cells by panning. Consistent with the expression of only p55 IL-2R, the functional activity of IL-2 on enriched CD34+ cells exposed to IL-3 could not be demonstrated in either granulocyte-macrophage colony-forming unit (CFU-GM) assays or proliferation assays.(ABSTRACT TRUNCATED AT 400 WORDS)
人白细胞介素3(IL-3)是一种多潜能细胞因子,可支持早期造血祖细胞的生长,并促进其对其他后期作用细胞因子的反应。我们发现,IL-3能够诱导正常人骨髓中一部分早期髓样细胞表达白细胞介素2(IL-2)受体(IL-2R)(CD25),这些骨髓细胞先用大豆凝集素和绵羊红细胞处理以去除成熟造血细胞和E玫瑰花结阳性T细胞(SBA-E-BM)。免疫荧光分析显示,CD25+细胞几乎完全包含在IL-3培养的骨髓的淋巴母细胞门内。新鲜分离的骨髓中未检测到CD25,在37℃下于10%人血清、10%胎牛血清存在下或无血清条件下进行液体培养后,可检测到的CD25+细胞少于10%。添加IL-3(100 U/ml)可使CD25的表达分别显著增加至37%、31%和24%。粒细胞-巨噬细胞集落刺激因子(GM-CSF)也可诱导CD25表达,但暴露于粒细胞集落刺激因子(G-CSF)、巨噬细胞集落刺激因子(M-CSF)、白细胞介素1(IL-1)、白细胞介素4(IL-4)或IL-2后未检测到IL-2R。CD25的表达取决于添加的IL-3或GM-CSF的剂量,且在暴露后24小时内达到最大值。双色免疫荧光分析表明,淋巴系细胞或成熟单核细胞不表达CD25,而是存在于共表达CD13、CD33、CD34、MY8和HLA-DR且缺乏CD14或CD11b的细胞上,因此将CD25+细胞置于分化的成髓细胞阶段或接近该阶段。GM-CSF诱导的CD25+细胞具有相同的表型。放线菌酮完全抑制IL-3诱导的CD25表达,表明蛋白质合成的必要性,尽管大多数CD25+细胞处于G0/G1期,但25%的细胞处于S期或G2M期,表明受体表达不依赖细胞周期。在CD25+细胞上未检测到IL-2R的p75链。通过淘选富集CD34+细胞的SBA-E-BM中,IL-3还能直接诱导超过46%的细胞表达CD25。与仅表达p55 IL-2R一致,在粒细胞-巨噬细胞集落形成单位(CFU-GM)试验或增殖试验中,均未证明IL-2对暴露于IL-3的富集CD-34+细胞具有功能活性。(摘要截短于400字)